
Please try another search
Protara Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is focused on identifying therapies for the treatment of cancer and rare diseases. The Company's pipeline includes TARA-002 and IV Choline Chloride. The Company's lead product pipeline is TARA 002 for the treatment of non-muscle invasive bladder cancer (NMIBC) and Lymphatic Malformations (LMs). TARA 002 is a cellular therapy based on OK-432, also known as Picibanil, which is derived from a genetically distinct strain of Streptococcus Pyogenes. IV choline chloride is an investigational, intravenous (IV) phospholipid substrate replacement therapy, which is in development for patients receiving parenteral nutrition (PN) who have intestinal failure-associated liver disease (IFALD).
Name | Age | Since | Title |
---|---|---|---|
Barry P. Flannelly | 63 | 2020 | Independent Director |
Cynthia Smith | 52 | 2021 | Independent Director |
Gregory P. Sargen | 55 | 2019 | Independent Director |
Richard S. Levy | 63 | 2019 | Independent Director |
Roger J. Garceau | 67 | 2019 | Independent Director |
Edna Huang | 48 | 2021 | Director |
Michael E. Solomon | 51 | 2020 | Independent Director |
Luke M. Beshar | 62 | 2018 | Independent Chairman of the Board |
Jesse Shefferman | 51 | 2017 | Co-Founder, CEO, President & Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review